These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18302508)

  • 41. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
    Kassem M
    APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest.
    Jobke B; Pfeifer M; Minne HW
    Connect Tissue Res; 2009; 50(1):46-54. PubMed ID: 19212852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The teriparatide in the treatment of severe senile osteoporosis.
    Manuele S; Sorbello L; Puglisi N; Grasso S; La Malfa L; D'Urbino G; Rizzotto M; Strano S; Maugeri D
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study.
    Sornay-Rendu E; Boutroy S; Munoz F; Delmas PD
    J Bone Miner Res; 2007 Mar; 22(3):425-33. PubMed ID: 17181395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is cortical bone hip? What determines cortical bone properties?
    Epstein S
    Bone; 2007 Jul; 41(1 Suppl 1):S3-8. PubMed ID: 17466615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.
    Motyckova G; Fisher DE
    Curr Mol Med; 2002 Aug; 2(5):407-21. PubMed ID: 12125807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Changes in bone quality and strength with bone-forming agents].
    Miyakoshi N
    Clin Calcium; 2016 Jan; 26(1):117-24. PubMed ID: 26728538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pedicle stress fracture: an unusual complication of pycnodysostosis.
    Ornetti P; Prati C; Fery-Blanco C; Streit G; Toussirot E; Wendling D
    Clin Rheumatol; 2008 Mar; 27(3):385-7. PubMed ID: 17891524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. About the comparison of two anabolic agents, teriparatide and strontium ranelate, in treated osteoporotic women.
    Meunier PJ; Boivin G; Marie PJ
    J Bone Miner Res; 2009 Dec; 24(12):2066; author reply 2067-8. PubMed ID: 19839763
    [No Abstract]   [Full Text] [Related]  

  • 53. Novel mutations of the cathepsin K gene in patients with pycnodysostosis and their characterization.
    Fujita Y; Nakata K; Yasui N; Matsui Y; Kataoka E; Hiroshima K; Shiba RI; Ochi T
    J Clin Endocrinol Metab; 2000 Jan; 85(1):425-31. PubMed ID: 10634420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased Bone Resorption during Lactation in Pycnodysostosis.
    Jansen IDC; Papapoulos SE; Bravenboer N; de Vries TJ; Appelman-Dijkstra NM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence.
    Chen W; Yang S; Abe Y; Li M; Wang Y; Shao J; Li E; Li YP
    Hum Mol Genet; 2007 Feb; 16(4):410-23. PubMed ID: 17210673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and genetic evaluation of Danish patients with pycnodysostosis.
    Doherty MA; Langdahl BL; Vogel I; Haagerup A
    Eur J Med Genet; 2021 Feb; 64(2):104135. PubMed ID: 33429075
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.
    Gelb BD; Shi GP; Chapman HA; Desnick RJ
    Science; 1996 Aug; 273(5279):1236-8. PubMed ID: 8703060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New anabolic therapies for osteoporosis.
    Minisola S; Cipriani C; Occhiuto M; Pepe J
    Intern Emerg Med; 2017 Oct; 12(7):915-921. PubMed ID: 28780668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of cathepsin K in normal bone resorption.
    Troen BR
    Drug News Perspect; 2004; 17(1):19-28. PubMed ID: 14993931
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pharmacology of bone anabolic agents].
    Matsumoto T
    Nihon Rinsho; 2015 Oct; 73(10):1639-44. PubMed ID: 26529924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.